GSK stock: Court upholds vaccine patent against Pfizer, BioNTech

Published on 11/13/2026 at 17:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

GSK stock is in focus after a Hague court upheld a key vaccine patent against Pfizer and BioNTech. The ruling could strengthen licensing leverage.

Patent ruling reshapes vaccine outlook

A Hague court upheld GSK's vaccine-delivery patent against Pfizer and BioNTech across a broad group of European jurisdictions.
Enforcement depends on the final validity decision and a possible licence agreement within three months.
The ruling adds commercial leverage, while appeals and two further patents keep the dispute open.

GSK, GB00BN7SWP63, Illustration mit AI erstellt.

GSK's vaccine patent dispute with Pfizer and BioNTech moved in the company's favor on Thursday, November 12, 2026, after the Local Division of the Unified Patent Court in The Hague upheld European patent EP 2 590 626 almost in full. JUVE Patent reported the decision on November 12.

Broad European reach

The patent covers liposomes used to deliver RNA in vaccines. The court found that BioNTech and Pfizer infringe the patent and extended the injunction across the European Patent Convention countries where the patent remains valid, excluding Ireland and the United Kingdom.

Only one claim was revoked, while the remaining claims survived five invalidity challenges. The decision therefore gives GSK a stronger negotiating position around technology used in RNA vaccine manufacturing.

Licence talks remain central

The injunction is not immediately enforceable. The court postponed enforcement until a final decision on the patent's validity and said it would take effect if Pfizer and BioNTech fail to reach a licence agreement with GSK within three months of that decision.

The manufacturers must also provide sales information reaching back to January 2020. The court awarded interim damages of 2 million euros and set the case value at 50 million euros.

Appeals keep dispute open

Pfizer and BioNTech can appeal and have already brought parallel validity proceedings in the United Kingdom and Ireland. Two additional GSK patents remain pending before the Hague division, leaving further legal steps ahead for investors to monitor.

Separately, GSK and Moderna have settled a related vaccine patent dispute through a cross-licensing arrangement, according to the JUVE Patent report. No payment was exchanged, and the agreement covered Moderna's Spikevax, mNEXSPIKE and RSV vaccine mResvia.